Cushing's Disease
27
3
3
15
Key Insights
Highlights
Success Rate
79% trial completion
Published Results
13 trials with published results (48%)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
14.8%
4 terminated out of 27 trials
78.9%
-7.6% vs benchmark
37%
10 trials in Phase 3/4
87%
13 of 15 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 15 completed trials
Clinical Trials (27)
DDAVP for Pituitary Adenoma
Cushing's Disease Complications
A Trial of Lu AG13909 in Adult Participants With Cushing's Disease
Assessment of Persistent Cognitive Impairment After Cure of Cushing's Disease
Collecting Information About Treatment Results for Patients With Cushing's Syndrome
Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's Disease
Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease
Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
Treatment of Cushing's Disease With R-roscovitine
Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease
Safety and Efficacy of LCI699 in Cushing's Disease Patients
Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease
Long-term Cardiovascular Risk in Cured Cushing's Patients
Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)
Seoul National University Pituitary Disease Cohort Study
Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly
Rhinological Outcomes in Endonasal Pituitary Surgery
An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.